PerkinElmer acquires Improvision for 3-D cell imaging capability
Waltham, MA--PerkinElmer, a technology developer in health sciences and photonics, acquired Improvision (Coventry, United Kingdom) in a cash transaction. Improvision is a provider of cellular imaging software and integrated hardware solutions used in life sciences research and had revenue of approximately $11.9 million dollars in 2006.
A major challenge facing cell biologists and researchers today is the efficient management of the abundance of data derived from high-content screening (HCS) and advanced confocal microscopy. The addition of Improvision's robust three-dimensional (3-D) imaging and analysis software to PerkinElmer's advanced HCS systems will provide customers with easy-to-use imaging solutions for analyzing cellular events—from real-time imaging of live cells to rapid high-content screening of multiple samples.
"This acquisition strengthens our leading capability in the fast-growing field of advanced cellular sciences," said Gregory L. Summe, chairman and CEO, PerkinElmer. "PerkinElmer now provides pharmaceutical and academic researchers with a single source for imaging and analysis solutions that will help increase their understanding of disease mechanisms at the cellular level, potentially speeding the development of new therapies for conditions such as Alzheimer's, Parkinson's, diabetes and cancer."
This announcement builds upon PerkinElmer's recent acquisition of Evotec Technologies, a leading provider of high-performance cellular screening systems.
For more information, visit www.perkinelmer.com.